Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Center Detractor Speaks Out At FDA Radiation Meeting

This article was originally published in The Gray Sheet

Executive Summary

Managers in FDA's device center "ignored and suppressed" significant public health concerns about imaging systems in their past reviews of some such devices, according to a scientist who spoke at a recent FDA meeting

You may also be interested in...



FDA Advisors Will Scrutinize CT Colonography Evidence

Two FDA advisory panels will come together Sept. 9 to consider the latest evidence supporting computed tomography colonography as a general screening tool for colorectal cancer. The technique has been touted as a less invasive option to traditional colonoscopy, but its use has been strongly questioned due to risks from radiation exposure and false positives.

Washington Roundup, August 2012

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we report on recent FDA proposals to streamline the 510(k) and PMA submission processes and the ongoing investigation into FDA surveillance of CDRH employee whistleblowers.

Judge Orders FDA To Hand Over Whistleblower Surveillance Documents

In the latest turn of events for FDA, a federal judge has ordered the agency to hand over thousands of documents accumulated from monitoring employees’ communications.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel